Our pipeline

Grifols ever-evolving portfolio is focused on innovation in new products and therapies, continued improvement across all areas and new advances in industrial manufacturing systems and processes.

This table provides an overview of projects of Bioscience division in development:

All projects
  • All projects
  • Advanced therapies
  • Biosurgery
  • Hematology
  • Hepatology
  • Immunology
  • Intensive care
  • Neurology

Research / Pre-Clinical


Clinical Development

Albutein® for acute-on-chronic liver failure

New indication

Albutein® for liver cirrhosis

New indication

Alphanate® for immune tolerance induction in cases of Hemophilia A with inhibitors

Potential new indication for this factor VIII clotting concentrate

Immunoglobin for myasthenia gravis

New therapeutic indication with intravenous immunoglobin

Intravenous fibrinogen

New product to treat deficiencies

Thrombate® for cardiopulmonary bypass

New indication for this antithrombin product

VistaSeal® for pediatrics

Brief description: New indication for this fibrin sealant


Registration / Post-Launch

Albumin in bags

Brief description: New presentation for increased user convenience

Plastem® supplement for cell cultures

New product

Subcutaneous immunoglobulin

A new product to subcutaneously treat primary immunodeficiency to offers greater convenience to patients


Products and services

How can we help you?

Read more

Research areas

Grifols R&D+i projects focus on broadening the therapeutic potential of plasma proteins, enhancing the safety of blood transfusions, creating new solutions for hospital pharmacies and advancing intravenous therapies.

Read more


Financial and regulatory information for investors and shareholders.

Read more